Metformin may increase risk of cognitive impairment

Metformin may increase risk of cognitive impairment
Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in Diabetes Care.

(HealthDay)—Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in Diabetes Care.

Eileen M. Moore, Ph.D., of the University of Melbourne in Australia, and colleagues conducted a subgroup analysis involving 104 patients with type 2 diabetes and 22 patients with impaired who participated in the Australian Imaging, Biomarkers and Lifestyle study of aging. The authors sought to determine whether metformin, serum vitamin B12, or calcium supplements are associated with cognitive impairment in patients with diabetes.

The researchers found that, overall, patients with diabetes were 51 percent more likely to exhibit cognitive impairment than those without diabetes, and those taking metformin were more than twice as likely (2.23-fold) to exhibit cognitive impairment. After adjusting for age, sex, level of education, history of depression, serum vitamin B12, and metformin use, cognitive performance was improved for those patients who were also taking .

"Adequately powered, prospective, controlled trials are warranted to investigate further the association between diabetes, , and the effect of metformin therapy, as well as the possible amelioration using vitamin B12 and/or ," the authors write.

Several authors disclosed financial ties the biotechnology industry.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Imeglimin beneficial as add-on to metformin in T2DM

date Dec 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, ...

Recommended for you

USPSTF review: T2DM screening doesn't cut mortality

date Apr 14, 2015

(HealthDay)—Type 2 diabetes screening is not associated with improved mortality rates after 10 years of follow-up, according to a U.S. Preventive Services Task Force (USPSTF) review published online April ...

Effects of n-3 PUFAs on insulin sensitivity unclear

date Apr 14, 2015

(HealthDay)—Dietary n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), do not appear to have clinically meaningful effects on peripheral or hepatic ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.